{"name":"Kelun-Biotech","slug":"kelun-biotech","ticker":"6990.HK","exchange":"HKEX","domain":"kelun.com","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally. The company's product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB","hq":"Chengdu, China","founded":0,"employees":"2045","ceo":"","sector":"ADC / Biologics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":434.8,"stockChange":-17.6,"stockChangePercent":-3.89,"marketCap":"$14.9B","metrics":{"revenue":303299892.1184,"revenueGrowth":101.3,"grossMargin":71.9,"rdSpend":0,"netIncome":-56295563.24772416,"cash":659044264.1925324,"dividendYield":0,"peRatio":130.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":303299892.1184,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":303299892.1184},{"period":"2024-12-31","value":284895593.58965},{"period":"2023-12-31","value":227040585.01261},{"period":"2022-12-31","value":118485068.50141}],"grossProfit":217945361.22237,"grossProfitHistory":[{"period":"2025-12-31","value":217945361.22237},{"period":"2024-12-31","value":187713823.03289},{"period":"2023-12-31","value":111890029.05745},{"period":"2022-12-31","value":77685667.87584999}],"rdSpend":194496037.32475,"rdSpendHistory":[{"period":"2025-12-31","value":194496037.32475},{"period":"2024-12-31","value":177762163.77718},{"period":"2023-12-31","value":151945593.88982},{"period":"2022-12-31","value":124682619.31167999}],"sgaSpend":41961948.02732,"operatingIncome":-68708202.11984,"operatingIncomeHistory":[{"period":"2025-12-31","value":-68708202.11984},{"period":"2024-12-31","value":-31156800.94154},{"period":"2023-12-31","value":-66707052.446779996},{"period":"2022-12-31","value":-58057805.89256}],"netIncome":-56295562.06867,"netIncomeHistory":[{"period":"2025-12-31","value":-56295562.06867},{"period":"2024-12-31","value":-39316445.25582},{"period":"2023-12-31","value":-84616885.13718},{"period":"2022-12-31","value":-90801761.11523}],"eps":-1.66,"epsHistory":[{"period":"2025-12-31","value":-1.66},{"period":"2024-12-31","value":-1.2},{"period":"2023-12-31","value":-2.84},{"period":"2022-12-31","value":-2.539511}],"cash":490998534.82897997,"cashHistory":[{"period":"2025-12-31","value":490998534.82897997},{"period":"2024-12-31","value":197985742.87480998},{"period":"2023-12-31","value":231207657.17758998},{"period":"2022-12-31","value":17571002.00117}],"totalAssets":882602361.8246499,"totalLiabilities":165284970.51075,"totalDebt":13035033.26588,"equity":717317391.3139,"operatingCashflow":-26572933.131,"operatingCashflowHistory":[{"period":"2025-12-31","value":-26572933.131},{"period":"2024-12-31","value":-63340263.292899996},{"period":"2023-12-31","value":8777910.83943},{"period":"2022-12-31","value":-39917910.25919}],"capex":-18606948.4625,"capexHistory":[{"period":"2025-12-31","value":-18606948.4625},{"period":"2024-12-31","value":-11955461.80063},{"period":"2023-12-31","value":-12122150.5825},{"period":"2022-12-31","value":-5746709.9758399995}],"freeCashflow":-45179881.593499996,"dividendsPaid":null,"buybacks":null,"employees":2045,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":434.8,"previousClose":452.4,"fiftyTwoWeekHigh":581,"fiftyTwoWeekLow":296.2,"fiftyTwoWeekRange":"296.2 - 581.0","fiftyDayAverage":454.18,"twoHundredDayAverage":448.81,"beta":-0.03,"enterpriseValue":14296918716.02565,"forwardPE":130.8,"priceToBook":18.07,"priceToSales":49.27,"enterpriseToRevenue":47.14,"enterpriseToEbitda":-265.93,"pegRatio":0,"ebitda":-53762068.26331584,"ebitdaMargin":-17.7,"freeCashflow":-26837427.99260448,"operatingCashflow":-26572933.131,"totalDebt":13035033.26588,"debtToEquity":1.8,"currentRatio":5.13,"returnOnAssets":-5.1,"returnOnEquity":-9.3,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":17,"targetMeanPrice":533.85,"targetHighPrice":624.96,"targetLowPrice":438.3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":62.8,"institutionHeldPercent":25.5,"sharesOutstanding":170984257,"floatShares":93087839,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-1.9,"epsForward":3.32,"revenuePerShare":8.93,"bookValue":24.06,"officers":[{"age":53,"name":"Dr. Junyou  Ge","title":"President, CEO, COO, GM & Executive Director"},{"age":42,"name":"Mr. Zejian  Zhou","title":"CFO & Joint Company Secretary"},{"age":39,"name":"Mr. Nan Chao  Ding","title":"Deputy GM & Chief Marketing Officer"},{"age":59,"name":"Mr. Yi  Feng","title":"Deputy GM, Chief Strategy Officer & Senior VP"},{"age":62,"name":"Dr. Xiangyang  Tan","title":"Deputy GM & Chief Scientific Officer of Large Molecule"},{"age":47,"name":"Dr. Xiaoping  Jin","title":"Deputy GM & Chief Medical Officer"},{"age":58,"name":"Dr. Wensheng  Yu","title":"Deputy General Manager & Chief Science Officer of Small Molecule"},{"age":50,"name":"Mr. Wei  Chen","title":"Deputy General Manager"}],"industry":"Biotechnology","irWebsite":"","website":"https://kelun-biotech.com","phone":""}}